Stacie Nguyen, Leo Baggerly, and Christine French are with GrassrootsHealth, Encinitas, CA. Robert P. Heaney is with Creighton University, Osteoporosis Research Center, Omaha, NE. Edward D. Gorham and Cedric F. Garland are with the Department of Family and Preventive Medicine, University of California San Diego, La Jolla.
Am J Public Health. 2014 Sep;104(9):1783-7. doi: 10.2105/AJPH.2013.301368. Epub 2013 Oct 17.
Increasing 25-hydroxyvitamin D serum levels can prevent a wide range of diseases. There is a concern about increasing kidney stone risk with vitamin D supplementation. We used GrassrootsHealth data to examine the relationship between vitamin D status and kidney stone incidence.
The study included 2012 participants followed prospectively for a median of 19 months. Thirteen individuals self-reported kidney stones during the study period. Multivariate logistic regression was applied to assess the association between vitamin D status and kidney stones.
We found no statistically significant association between serum 25-hydroxyvitamin D and kidney stones (P = .42). Body mass index was significantly associated with kidney stone risk (odds ratio = 3.5; 95% confidence interval = 1.1, 11.3).
We concluded that a serum 25-hydroxyvitamin D level of 20 to 100 nanograms per milliliter has no significant association with kidney stone incidence.
提高 25-羟维生素 D 血清水平可以预防多种疾病。人们担心维生素 D 补充会增加肾结石的风险。我们利用 GrassrootsHealth 数据来研究维生素 D 状态与肾结石发病率之间的关系。
本研究纳入了 2012 名参与者，前瞻性随访中位数为 19 个月。在研究期间，有 13 名参与者自述患有肾结石。多变量逻辑回归用于评估维生素 D 状态与肾结石之间的关系。
我们发现血清 25-羟维生素 D 与肾结石之间无统计学显著关联（P =.42）。体重指数与肾结石风险显著相关（比值比 = 3.5；95%置信区间 = 1.1, 11.3）。
我们得出结论，血清 25-羟维生素 D 水平在 20 至 100 纳克/毫升之间与肾结石发病率无显著关联。
